A mathematical model for predicting tumor recurrence within 24 months following surgery in patients with T1 high-grade bladder cancer treated with BCG immunotherapy
Main Article Content
Keywords
bladder cancer, decision tree model, neutrophils-to-lymphocytes ratio
Abstract
Objectives: Aggressive bladder cancer has a high rate of recurrence and progression. Treatment of T1 high-grade (T1HG) bladder cancer lesions is challenging. Current prognostic models reasonably predict progression; however, additional prognostic markers are required to accurately predict recurrence. The aim of the study was to develop a prediction model for risk of recurrence in individual patients with T1HG bladder cancer treated with intravesical BCG.
Patients and Methods: Medical records of 115 patients with T1HG bladder cancer treated with adjuvant intravesical BCG immunotherapy from two different hospitals were reviewed. Mathematical algorithms were applied to identify parameters that could accurately predict recurrence within 24 months after surgery.
Results: Overall recurrence rate at 24 months after surgery was 49%. Of all clinical and pathological parameters evaluated, the best predictor of recurrence within 24 months after surgery was neutrophils-to-lymphocytes ratio. This ratio predicted recurrence with 86% sensitivity and 62% specificity in the whole database. The main limitations of our study are its retrospective nature and the small patient number.
Conclusions: Neutrophils-to-lymphocytes ratio was found to be superior to traditional parameters for the prediction of recurrence within 24 months following surgery in patients with T1HG bladder cancer treated with intravesical BCG immunotherapy. Stratifying patients using risk factors can help determine the appropriate follow-up and treatment for each individual patient.
Metrics
References
2. Burger M, Catto JWF, Dalbagni G, et al (2013) Epidemiology and Risk Factors of Urothelial Bladder Cancer. Eur Urol 63(2):234-241.
3. Sylvester RJ, van der Meijden APM, Oosterlinck W, et al (2006) Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC Trials. Eur Urol 49(3):466-477.
4. Babjuk M, Burger M, Zigeuner R, et al (2013) EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013. Eur Urol 64(4):639-653.
5. Vedder MM, Márquez M, de Bekker-Grob EW, et al (2014) Risk Prediction Scores for Recurrence and Progression of Non-Muscle Invasive Bladder Cancer: An International Valida
Article Sidebar
Article Details
Authors who publish with the Bladder agree to the following terms:
- Authors retain copyright and grant the Bladder right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
